Search research articles
Contact Us
Filters
Showing results (171-180 of 178) with videos related to
Page
of 18
Sort By:
You have reached the last page of results.
This site can display upto 178 results.
European Journal of Cancer (Oxford, England : 1990)
|
November 27, 2024
Impact of personalized response-directed surgery and adjuvant therapy on survival after neoadjuvant immunotherapy in stage III melanoma: Comparison of 3-year data from PRADO and OpACIN-neo
Irene L M Reijers, Alexander M Menzies, Marta Lopez-Yurda, et al.
Vaccine
|
November 11, 2024
Phase II study on the safety and immunogenicity of single-dose intramuscular or intranasal administration of the AVX/COVID-12 "Patria" recombinant Newcastle disease virus vaccine as a heterologous booster against COVID-19 in Mexico
Constantino López-Macías, Martha Torres, Brenda Armenta-Copca, et al.
Science Advances
|
June 27, 2025
Phase 2/3 study evaluating safety, immunogenicity, and noninferiority of single booster dose of AVX/COVID-12 vaccine
Constantino López-Macías, Martha Torres, Brenda Armenta-Copca, et al.
Reports on Progress in Physics. Physical Society (Great Britain)
|
April 7, 2025
Gravitational wave astronomy with TianQin
En-Kun Li, Shuai Liu, Alejandro Torres-Orjuela, et al.
Nature Medicine
|
June 6, 2022
Personalized response-directed surgery and adjuvant therapy after neoadjuvant ipilimumab and nivolumab in high-risk stage III melanoma: the PRADO trial
Irene L M Reijers, Alexander M Menzies, Alexander C J van Akkooi, et al.
Nature Medicine
|
January 28, 2026
Neoadjuvant ipilimumab plus nivolumab in melanoma: 5-year survival and biomarker analysis from the phase 2 PRADO-trial
Lotte L Hoeijmakers, Petros Dimitriadis, Steven C M A Wijnen, et al.
The New England Journal of Medicine
|
December 8, 2022
Tumor-Infiltrating Lymphocyte Therapy or Ipilimumab in Advanced Melanoma
Maartje W Rohaan, Troels H Borch, Joost H van den Berg, et al.
The New England Journal of Medicine
|
June 3, 2024
Neoadjuvant Nivolumab and Ipilimumab in Resectable Stage III Melanoma
Christian U Blank, Minke W Lucas, Richard A Scolyer, et al.
Page
of 18
Search research articles
Search
Showing results (171-180 of 178) with videos related to
Sort By:
Page
of 18
You have reached the last page of results.
This site can display upto 178 results.
European Journal of Cancer (Oxford, England : 1990)
|
November 27, 2024
Impact of personalized response-directed surgery and adjuvant therapy on survival after neoadjuvant immunotherapy in stage III melanoma: Comparison of 3-year data from PRADO and OpACIN-neo
Irene L M Reijers, Alexander M Menzies, Marta Lopez-Yurda, et al.
Vaccine
|
November 11, 2024
Phase II study on the safety and immunogenicity of single-dose intramuscular or intranasal administration of the AVX/COVID-12 "Patria" recombinant Newcastle disease virus vaccine as a heterologous booster against COVID-19 in Mexico
Constantino López-Macías, Martha Torres, Brenda Armenta-Copca, et al.
Science Advances
|
June 27, 2025
Phase 2/3 study evaluating safety, immunogenicity, and noninferiority of single booster dose of AVX/COVID-12 vaccine
Constantino López-Macías, Martha Torres, Brenda Armenta-Copca, et al.
Reports on Progress in Physics. Physical Society (Great Britain)
|
April 7, 2025
Gravitational wave astronomy with TianQin
En-Kun Li, Shuai Liu, Alejandro Torres-Orjuela, et al.
Nature Medicine
|
June 6, 2022
Personalized response-directed surgery and adjuvant therapy after neoadjuvant ipilimumab and nivolumab in high-risk stage III melanoma: the PRADO trial
Irene L M Reijers, Alexander M Menzies, Alexander C J van Akkooi, et al.
Nature Medicine
|
January 28, 2026
Neoadjuvant ipilimumab plus nivolumab in melanoma: 5-year survival and biomarker analysis from the phase 2 PRADO-trial
Lotte L Hoeijmakers, Petros Dimitriadis, Steven C M A Wijnen, et al.
The New England Journal of Medicine
|
December 8, 2022
Tumor-Infiltrating Lymphocyte Therapy or Ipilimumab in Advanced Melanoma
Maartje W Rohaan, Troels H Borch, Joost H van den Berg, et al.
The New England Journal of Medicine
|
June 3, 2024
Neoadjuvant Nivolumab and Ipilimumab in Resectable Stage III Melanoma
Christian U Blank, Minke W Lucas, Richard A Scolyer, et al.
Page
of 18